Junko Hamamoto

1.7k total citations
27 papers, 808 citations indexed

About

Junko Hamamoto is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Junko Hamamoto has authored 27 papers receiving a total of 808 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 17 papers in Pulmonary and Respiratory Medicine and 10 papers in Oncology. Recurrent topics in Junko Hamamoto's work include Lung Cancer Treatments and Mutations (15 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Cancer therapeutics and mechanisms (5 papers). Junko Hamamoto is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Cancer therapeutics and mechanisms (5 papers). Junko Hamamoto collaborates with scholars based in Japan, United States and France. Junko Hamamoto's co-authors include Hiroyuki Yasuda, Kenzo Soejima, Katsuhiko Naoki, Tomoko Betsuyaku, Ichiro Kawada, Shigenari Nukaga, Daisuke Arai, Keita Masuzawa, Toshiyuki Hirano and Tetsuo Tani and has published in prestigious journals such as Cancer Research, Biochemical and Biophysical Research Communications and Frontiers in Immunology.

In The Last Decade

Junko Hamamoto

25 papers receiving 804 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Junko Hamamoto Japan	16	535	446	408	153	61	27	808
Assunta Sgambato Italy	15	416 0.8×	441 1.0×	293 0.7×	125 0.8×	53 0.9×	31	742
Francesca Casaluce Italy	15	462 0.9×	512 1.1×	326 0.8×	140 0.9×	56 0.9×	38	841
Songwen Zhou China	17	280 0.5×	236 0.5×	425 1.0×	291 1.9×	68 1.1×	39	724
Youwei Bi United States	14	307 0.6×	275 0.6×	225 0.6×	89 0.6×	55 0.9×	25	768
Mingwei Chen China	15	228 0.4×	219 0.5×	404 1.0×	122 0.8×	65 1.1×	41	658
George Blumenschein United States	6	433 0.8×	675 1.5×	388 1.0×	104 0.7×	40 0.7×	8	906
Kenichi Chikamori Japan	16	423 0.8×	502 1.1×	386 0.9×	65 0.4×	32 0.5×	43	812
Millie Das United States	17	388 0.7×	405 0.9×	287 0.7×	145 0.9×	31 0.5×	63	719
Jia Zhong China	16	368 0.7×	346 0.8×	221 0.5×	175 1.1×	34 0.6×	57	697
Shigenari Nukaga Japan	9	398 0.7×	319 0.7×	224 0.5×	84 0.5×	35 0.6×	21	501

Countries citing papers authored by Junko Hamamoto

Since Specialization

Citations

This map shows the geographic impact of Junko Hamamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junko Hamamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junko Hamamoto more than expected).

Fields of papers citing papers by Junko Hamamoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junko Hamamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junko Hamamoto. The network helps show where Junko Hamamoto may publish in the future.

Co-authorship network of co-authors of Junko Hamamoto

This figure shows the co-authorship network connecting the top 25 collaborators of Junko Hamamoto. A scholar is included among the top collaborators of Junko Hamamoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junko Hamamoto. Junko Hamamoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chubachi, Shotaro, Jun Miyata, Junko Hamamoto, et al.. (2025). Celecoxib prevents malignant progression of smoking-induced lung tumors via suppression of the COX-2/PGE2 signaling pathway in mice. Frontiers in Immunology. 16. 1557790–1557790.

Satō, Takashi, Junko Hamamoto, Katsura Emoto, et al.. (2022). Abstract 5715: Epigenomic profiling identifies distinct neuroendocrine subtypes in lung cancer with neuroendocrine differentiation. Cancer Research. 82(12_Supplement). 5715–5715.

Ebisudani, Toshiki, Shinya Sugimoto, Kei Haga, et al.. (2021). Direct derivation of human alveolospheres for SARS-CoV-2 infection modeling and drug screening. Cell Reports. 35(10). 109218–109218. 41 indexed citations

Terai, Hideki, Junko Hamamoto, Katsura Emoto, et al.. (2020). SHOC2 Is a Critical Modulator of Sensitivity to EGFR–TKIs in Non–Small Cell Lung Cancer Cells. Molecular Cancer Research. 19(2). 317–328. 13 indexed citations

Manabe, Tadashi, Hiroyuki Yasuda, Hideki Terai, et al.. (2020). IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer. Molecular Cancer Research. 18(4). 549–559. 39 indexed citations

Yoshimoto, Yuya, Yasushi Sasaki, Kazutoshi Murata, et al.. (2020). Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy. Gynecologic Oncology. 159(2). 546–553. 20 indexed citations

Yasuda, Hiroyuki, Keigo Kobayashi, Tetsuo Tani, et al.. (2019). Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab. Molecular Cancer Therapeutics. 18(9). 1593–1601. 3 indexed citations

Hirano, Toshiyuki, Hiroyuki Yasuda, Junko Hamamoto, et al.. (2018). Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR -Mutated Non–Small Cell Lung Cancer. Molecular Cancer Therapeutics. 17(4). 740–750. 31 indexed citations

Hegab, Ahmed E., Mari Ozaki, Shizuko Kagawa, et al.. (2018). Tumor associated macrophages support the growth of FGF9-induced lung adenocarcinoma by multiple mechanisms. Lung Cancer. 119. 25–35. 27 indexed citations

10.

Yasuda, Hiroyuki, Junko Hamamoto, Keita Masuzawa, et al.. (2018). Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations. Lung Cancer. 127. 146–152. 40 indexed citations

11.

Nukaga, Shigenari, Hiroyuki Yasuda, Katsuya Tsuchihara, et al.. (2017). Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. Cancer Research. 77(8). 2078–2089. 131 indexed citations

12.

Hamamoto, Junko, Hiroyuki Yasuda, Makoto Nishino, et al.. (2017). Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors. Oncology Letters. 14(3). 3559–3565. 13 indexed citations

13.

Nishino, Makoto, Mari Ozaki, Ahmed E. Hegab, et al.. (2017). Variant CD44 expression is enriching for a cell population with cancer stem cell-like characteristics in human lung adenocarcinoma. Journal of Cancer. 8(10). 1774–1785. 30 indexed citations

14.

Miyawaki, Masayoshi, Hiroyuki Yasuda, Tetsuo Tani, et al.. (2016). Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer. Molecular Cancer Research. 15(1). 106–114. 58 indexed citations

15.

Tani, Tetsuo, Hiroyuki Yasuda, Junko Hamamoto, et al.. (2015). Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK -Translocated Lung Cancer Cells. Molecular Cancer Therapeutics. 15(1). 162–171. 54 indexed citations

16.

Ohgino, Keiko, Hiroyuki Yasuda, Junko Hamamoto, et al.. (2015). Abstract 4: ABT-263 is effective in a subset of non-small cell lung cancer cell lines. Cancer Research. 75(15_Supplement). 4–4. 4 indexed citations

17.

Terai, Hideki, Kenzo Soejima, Hiroyuki Yasuda, et al.. (2014). Long-term exposure to gefitinib induces acquired resistance through DNA methylation changes in the EGFR-mutant PC9 lung cancer cell line. International Journal of Oncology. 46(1). 430–436. 12 indexed citations

18.

Suzuki, Takahiro, Hiroyuki Yasuda, Daisuke Arai, et al.. (2014). Multiple roles of extracellular fibroblast growth factors in lung cancer cells. International Journal of Oncology. 46(1). 423–429. 16 indexed citations

19.

Hamamoto, Junko, et al.. (2013). Impacts of the introduction of a triage system in Japan: A time series study. International Emergency Nursing. 22(3). 153–158. 23 indexed citations

20.

Naoki, Katsuhiko, Kenzo Soejima, Hiroaki Okamoto, et al.. (2011). The PCR-invader method (structure-specific 5′ nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing. International Journal of Clinical Oncology. 16(4). 335–344. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact